In CRC, MGMT methylation associated positively with KRAS mutations (28% vs. 52% p = 0.0006) and negatively with TP53 mutations (47% vs 27%, p = 0.002) (Figure 2 top). This evidence concerns the gene KRAS and colorectal carcinoma.